Different types of Drug-induced Liver Injury (DILI) Drug-induced liver injury (DILI) is a longstanding and significant problem for clinicians,
CN Bio appoints Deepak Singh as Vice President of Sales and Marketing
Cambridge, UK, 14 March 2023: CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological
CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System
Cambridge, UK, CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS),
The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system
Cambridge, UK, 17th January 2023: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ
The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.
What is the FDA Modernization Act 2.0, and what does it mean? The U.S. Food and Drug Administration (FDA) are the federal agency tasked with
CN Bio appoints Dr Paul Brooks as Chief Executive Officer
Key strategic appointment as the Company enters next phase of commercial growth and global expansion of its products and services. Former CEO, Dr
Pharmacokinetics in mice… or a microfluidic device!
Xenograft models have long been the gold standard method for preclinically assessing the relationship between PK/PD and efficacy. However,
CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities
State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services Cambridge,
MPS World Summit Round-up
If you could not attend the inaugural Microphysiological System (MPS) World Summit in New Orleans earlier this month, but it is on